![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
1. 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide
2. 4-(3-chloro-4-((cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide
3. 4-(3-chloro-4-(n'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide
4. E 7080
5. E-7080
6. E-7080 Mesylate
7. E7080
8. E7080 Mesylate
9. Er-203492-00
10. Lenvatinib
11. Lenvatinib Mesilate
12. Lenvatinib Metabolite M2
13. Lenvatinib Methanesulfonate
14. Lenvima
15. N-(4-((6-carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)-n'-cyclopropylurea Monomethanesulfonate
1. 857890-39-2
2. Lenvima
3. Lenvatinibmesylate
4. Lenvatinib Mesilate
5. Lenvatinib Mesylate [usan]
6. E7080 Mesylate
7. Lenvatinib (mesylate)
8. Unii-3j78384f61
9. E-7080 Mesylate
10. Chebi:85995
11. 857890-39-2 (mesylate)
12. 3j78384f61
13. Lenvatinib Mesilate (jan)
14. Lenvatinib Mesylate (usan)
15. N-(4-((6-carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)-n'-cyclopropylurea Monomethanesulfonate
16. Lenvatinib Mesilate [jan]
17. 4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide Mesylate
18. 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide;methanesulfonic Acid
19. 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide Monomethanesulfonate
20. Lenvima (tn)
21. E7080mesylate
22. E7080 (mesylate)
23. Lenvatinib Methanesulfonate
24. Lenvatinib Mesylate- Bio-x
25. Schembl865174
26. Amy385
27. Chembl2105704
28. Dtxsid90235081
29. Bcp11858
30. Hy-10981a
31. Lenvatinib Mesilate [who-dd]
32. Mfcd18633219
33. Ccg-269873
34. Sb16581
35. Lenvatinib Methanesulfonate [mi]
36. Lenvatinib Mesylate [orange Book]
37. Ac-30100
38. Bl166696
39. Ds-19245
40. Cs-0030963
41. S5240
42. D09920
43. A900902
44. Q27158839
45. 4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide Methanesulfonate
46. 6-carbamoyl-4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinolin-1-ium Methanesulfonate
47. 6-quinolinecarboxamide, 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)- 7-methoxy-, Methanesulfonate (1:1)
48. 6-quinolinecarboxamide, 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-, Methanesulfonate (1:1)
49. Methanesulfonic Acid--4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide (1/1)
Molecular Weight | 523.0 g/mol |
---|---|
Molecular Formula | C22H23ClN4O7S |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 6 |
Exact Mass | 522.0975980 g/mol |
Monoisotopic Mass | 522.0975980 g/mol |
Topological Polar Surface Area | 178 Ų |
Heavy Atom Count | 35 |
Formal Charge | 0 |
Complexity | 727 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Lenvima is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hrthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).
Lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
L01XE